Skip to main content

Avalon, Cellex Ink Commercialization, Distribution Agreement for COVID-19 Antibody Tests

NEW YORK ─ Avalon GloboCare said on Wednesday that it has entered into a commercialization partnership to market and distribute Cellex's COVID-19 antibody-based rapid test kit.

This agreement allows Avalon, a developer of cell-based technologies and therapeutics, to initiate distribution and marketing of the test to its designated network of channel partners and distributor affiliates in the US and internationally.

Financial and other terms of the agreement were not disclosed.

In April, Cellex's test was the first serology test for SARS-CoV-2 to receive US Food and Drug Administration Emergency Use Authorization. The rapid test kits detect IgG and IgM antibodies specific to the SARS-CoV-2 that causes COVID-19 in serum, plasma, and whole blood within 15 minutes.

Freehold, New Jersey-based Avalon said it is also working with Durham, North Carolina-based Cellex to source manufacturing facilities and to develop next-generation COVID-19 detection kits.